News & Publications


Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

Prous Institute at Chem-Bio Informatics Society (CBI) Annual Meeting (Tokyo, Japan October 28-30, 2014)

Prous Institute has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting "iPS cells, Ion channels, in silico Technologies: Leading to a New Drug Discovery Paradigm" which takes place in Tokyo, Oct. 28-30, 2014.

During the CBI session "in silico approaches for drug targets" Oct. 29 (Wed) 14:00-15:30, Josep Prous, Jr., Ph.D., Vice President Research and Development, will present “Integrated in-silico approach to drug discovery and safety evaluation”, highlighting applications of the Symmetry platform through a series of case studies.

Prous Institute has developed Symmetry, the world’s first integrated in silico solution for drug discovery and safety screening. The platform integrates models for a wide range of efficacy, toxicology and human adverse events endpoints. Symmetry’s Global Mechanism of Action model predicts on- and off-target activities of small molecules and is based on a large training set of over 900,000 compounds with 1.5 million Structure-Activity Relationships (SAR).

Ryoka Systems, official distributor for Prous Institute Symmetry in Japan, will sponsor a session on Oct. 28 (Tues), “Increasing Productivity in Drug R&D”. The session will be chaired by Prof. Hirayama of Tokai University and include the talks “Computational Approaches to Drug Safety Assessment: US FDA / CDER Practices for ICH M7 (Q)SAR Computational Toxicology by R. Daniel Benz, Ph.D, former FDA/CDER computational toxicologist and founder of OmnyCorp; and “Next Generation Drug Repositioning Strategies” by Josep Prous, Jr., Ph.D.

In addition, Prous Institute will present a poster on Symmetry's Global Mechanism of Action (MoA) model including an application of the model to predict the relevant mechanisms of action associated with binary data. (Poster number P2-08).

For further information or to schedule a meeting during the conference, please contact


About Prous Institute for Biomedical Research:

Prous Institute for Biomedical Research is a research company comprised of two business units: drug discovery and in silico technologies. Prous Institute’s drug discovery and research unit is committed to discovering novel therapies through the application of its proprietary drug discovery platform, Symmetry. Prous Institute’s in silico technologies business unit fosters the development and commercialization of chemoinformatic and toxicity prediction technologies for regulatory and industry safety screening and drug discovery programs.

Prous Institute for Biomedical Research was founded as a spin-off from the leading scientific information provider, Prous Science (acquired by Thomson Reuters in 2007), in order to put into practice innovative in silico approaches to accelerate drug discovery. 

Prous Institute Symmetry integrates computational tools and methods aiming to replicate in silico the processes through which new drugs are discovered, developed and approved. Symmetry enables the generation of new research hypotheses and elucidates the pharmacological and safety profile of small molecules through a wide range of predictive models. Symmetry helps to “de-risk” and prioritize projects and speed up drug discovery and development, reducing time, costs and attrition rates. The underlying technology is based on a combination of advanced proprietary algorithms and a molecular descriptor approach which takes into account both structural features and physicochemical properties of small molecules.